Week 10 Flashcards
Snake envenoming DDx Bullous swelling on hand
Snake bite, necrotising fasciitis, burn, phytotoxicity
Snake envenoming Viperidae
Relatively short, thick, short-tailed, often with colourful dorsal pattern (V or U), slow-moving but lightning-striking, cytotoxic bite.
Snake envenoming Treatment
Antibiotics (superadded infection), Tetanus toxoid is essential for deep penetrating wound, Antivenom is only required for systemic illness in the initial phase, Surgical debridement is essential to attain source control
Snake envenoming Elapidae
Beautiful, graceful, hooded body (cobra), bands of colouring
Tunga penetrans Summary
Jigger flea. Over 1 billion people live in areas suitable for transmission of tungiasis. Adult female sand fleas burrow into the skin-shady soil. Adult females burrow in the stratum granulosum (usually feet). Pain and itching -> difficulty walking, sleeping and concentrating on school or work. Tungiasis can be associated with abscesses caused by secondary bacterial infections. Rx: remove with sterile needle, aim to remove as a whole, if pierced, eggs are laid everywhere. Antibiotic cover. Control = One Health approach (treating the patients, sealing/spraying floors with insecticide, daily foot washing with soap, treating infected animals owned by affected families.
Mycetoma (Madura foot) DDx
Bacteria: Actino, TB/NTM, Botryomycosis, Bacterial OM. Viral: Kaposi Sarcoma, Fungal: Basidiobolomycosis, Chromoblastomychosis, Non infections: Podoconiosis, malignant tumour (sarcoma)
Mycetoma (Madura foot) Summary
Chronic, suppurative, granulomatous subcutaneous infection caused by bacteria (actinomycetoma) or fungi (eumycetoma). Usually soil/water transmitted via broken skin. Incubation period: 3 months to many years. RF: living in endemic areas, low socioeconomic status, working in agriculture/farming, history of trauma, having poor health education, poor accessibility to healthcare, M:F 3:1. Mycetoma belt (latitudes 15o South and 30o North. Central/South America & parts of Asia = actinomycetoma commonest (dry areas). Africa eumycetoma = commonest (high rainfall). Classic triad: painless woody swelling, sinus tracts, grains. Deep incisional biopsies are preferred to superficial samples. Polymerase chain reaction (PCR) is the most reliable method but has high cost. Leading bacterial cause Nocardia asteroides (white grain), fungal Madurella mycetomatis (black/brown grain. XR: periosteal reaction, osteoporosis, osteolysis. MRI: pathognomonic dot in circle sign in bone. Prevention: Footwear - also protects against Hookworm, Strongyloides stercoralis, Podoconiosis, Tungiasis, Venom bites and stings.
Mycetoma (Madura foot) Comparison
Fungal: extremities, mainly foot. Slow progression, well encapsulated, clear margin. Few sinuses. Late bone invasion, punched out lytic lesions on XR. Long term antifungal and surgical intervention (itraconazole for years). Bacteria: mostly feet, trunk and head involvement has been seen. Rapid, diffuse, unclear margins, inflammation and destruction. Many sinuses. Early invasion of bones. Osteolytic and osteosclerotic lesions on XR. Antibiotics. Surgery not usually indicated. SXT +/- second agent for months to years. Treatment options not based on comprehensive clinical trials - expert/local opinion.
Mycetoma Summary
Chronic, suppurative, disfiguring granulomatous subcutaneous infection caused by bacteria (actinomycetoma - commonest nocardia) or fungi (eumycetoma - commonest Madurella sp). Usually soil/water transmitted via broken skin. Incubation period 3 months to many years. High risk individuals are those in remote communities with limited access to healthcare and medications in tropical/subtropical areas. M:F 3:1. Clinical triad of painless tissue swelling, sinus tracts producing grains. Firm, painless masses under the skin, untreated can destroy muscle and bone. Treatment lasts months to years. Eumycetoma: Itraconazole +/- surgery. Actinomycetoma: SXT = gold standard. Can be prevented with footwear. Numerous adverse medical, health and socioeconomic consequences for patients, communities and health services. On the WHO Neglected tropical diseases list.
Myiasis Summary
Cordylobia nathropophaga (In Africa Tumbu, mango fly) US can sometimes see larvae under skin. Prevention: insecticides (BHC, DDT, pyrethroids), drying clothes inside or ironing. Vaseline over the top to oxygen deprive. South America: Bot fly: Dermatobia hominis (oval shaped maggots) - harder to get out, still use occlusive therapy but need cruciate incision to remove.
Polio Introduction
Ancient disease, Egyptians described, in the last century. Enterovirus (RNA), three serotypes. Faecal-oral transmission (or pharyngeal). Virus to mucosa to lymphoid to CNS. Incubation 7-14d (3-35d) - flaccid paralysis (‘AFP’). Case infection ration 1/100 to 1/2000 (serotype 1>3>2)- increases with age, increase during 20th century (improved hygiene meant that children were infected at an older age, and therefore were more likely to be paralysed when they were infected)
Polio Vaccines
Salk (killed IPV vaccine). Sabin (live OPV vaccine). Incredible response in HIC countries. Campaigns of twice yearly vaccines for children 1-5yo - Cuba 1962, Brazil 1980. 1974 added to the expanded programme of immunisation. 1985 PAHO declared target to ‘eradicate’ (though we would call this elimination) poliomyelitis from Americas, 1988 World Health Assembly declaration to eradicate poliomyelitis from the world by 2000.
Polio Eradication strategy
1 High routine immunisation coverage (emphasis on OPV) 2 National Immunisation Days (NIDs) (OPV to all children under five, more than 1 billion doses of OPV per year). 3 Acute Flaccid Paralysis (AFP) surveillance (expect at least 1 per 100,000 under age 15). 4 Mop up campaigns (house to house). GPEI Progress from 1988 350,000 cases in 125 countries, from 2000 no type 2, 2003 <1000 cases in 6 countries (>99.7% decline - talk of ‘end game’. Endgame challenges: To finish off wild virus, financial, certification, containment, stopping OPV, security against reintroduction. Vaccine hesitancy in northern Nigeria 2003 -> wild polio got into Hajj population and transmission moved from Nigeria through Middle East to India. Politics challenge. Fake vaccination used to seek Osama Bin Laden’s family (sequencing of the needles) - this has severely affected vaccination campaigns and hesitancy. India conversely is the most heavily vaccinated populations anywhere, in history. Israel ‘silent circulation of WP1’ OPV discontinued 2005, >92 coverage 4 doses IPV, widespread routine environmental sampling - transmission occurring as IPV does not prevent infection (it prevents disease) - OPV reintroduced 2013. Global approach 2014 >=1 dose IPV in addition to the OPV (move from trivalent to bivalent OPV). 2016 to stop introducing type 2 virus and hence VDPV-2. Global withdrawal of trivalent OPV and destruction of remaining stock - global substitution of bivalent 1-3 OPV. Every vaccination centre in every LIC and most MIC. Following this: wild type Afghanistan Pakistan, Nigeria, increasing cases cVDPV2 across Africa.
Polio OPV
Why? Easy to administer, less expensive than IPV (does not need as much antigen as it is self-replicating)), greater enteric immunity (very effective against infection), Transmissible - so immunises more than those vaccinated. Disadvantages: lower seroconversion in tropics (probably due to competing bugs within the gut of children in the tropics, competitive inhibition), causes paralysis approximately 1 per million doses (risk is first dose, many HIC moved to IPV as they could no longer accept that risk), transmissibility is a two-edged sword. Millions of field staff involved - vaccination of young children in nomadic populations is key
Polio Vaccine-derived polio viruses
First recognised 2000 in Haiti (genomic identification) Note cVDPV ‘circulating vaccine-derived polio virus’ - defined as having circulated for more than one year and associated with ?1% change in VP1 gene. Outbreaks by 2007: more and more viruses typed - reverts to wildtype virulence and transmissibility. Mainly type 2 (with limited wild-type immunity in the population as it had been eliminated)
Polio Current situation
WPV1 Afghanistan, Pakistan. cVPDV central Africa, VDPV2 Africa, Middle East, Indonesia - these are just the ‘cases’
Polio End game
Stop all wild virus circulation, stop all VDPV circulation, security against reintroduction, to stop all vaccination (but need 100% removal before this is possible)
Polio Stop all wild virus
Afghanistan and Pakistan - two of the most difficult countries - Geopolitics - Patience, diplomacy, high coverage, time and money. Need to give armed cover for vaccinators (they have been attacked and killed regularly)
Polio Stop all VDPV
New vaccines: novel’ OPV eg nOPV2 (less likely to circulate than Sabin OPV2 >1 billion doses since 2021 (including 0.5mil in Nigeria, despite the hesitancy and history). VLP (virus-like-particle vaccine under development - uncertain whether it will induce sufficient mucosal immunity)
Polio Security against reintroduction
Continued circulation: surveillance sensitivity: cVDPV2 in sewage in ten countries with no cases over past year. ‘Sensitivity’ difficult to define (very low case/infection ratio). Vaccine manufacture: live vaccines best for mucosal immunity, but may escape (security is an issue). Stored samples (eg faecal samples in labs). Immunodeficient carriers (rare, but can excrete for many years, without clinical signs)
Polio To stop all vaccination
Ideally, to maximise dividend (as long as virus circulates anywhere, the entire world is at risk). Unlikely in near future.
Disability, stigma and resilience Disability
Persons with disabilities include those who have long-term physical, mental, intellectual or sensory impairments which in interaction with various barriers may hinder their full and effective participation in society on an equal basis with others. - UN Convention on the Rights for Persons with Disabilities. Key messages: people with disabilities face stigma which leads to social exclusion, discrimination, reduced social support, and lack of access to healthcare. Unless stigma is adequately considered and addressed, we will continue to fail people with disabilities.
Disability, stigma and resilience Epidemiology
According to the WHO globally, approximately 1.3 billion people; 16% of the world’s population have a significant disability. 240 million children with disabilities worldwide, 53 million under 5 years old. According to the World Bank 80% live in LMIC and have limited access to services to meet their needs. Discrimination, distress, exclusion. More likely to report ill health: Diabetes 3x, HIV/AIDS 2x, Catastrophic health expenditure 50x, Malnourished and die as a child x2.
Disability, stigma and resilience Needs of people with disabilities
Regular health needs (like anyone else), Higher vulnerability to poor health. Specialised medical treatment or rehabilitation services (in some but not all cases). Inaccessible transport, cost, inaccessible buildings, inaccessible equipment, HCW skills and attitude - caregivers are often blamed or dismissed. Challenges: limited knowledge of disability restricted ability to provide care, need for training and awareness raising, pressure of work and numbers mean limited capacity to respond.